STERIS plc
—- Market cap
- $21.90B
- Debt
- +$1.93B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 92% equity / 8% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $21.90B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: STE stock price at discount vs CTMX $224.63 current versus $649.36 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTMX's multiple
Implied fair value · at STE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: STE FY 2026 (ended Mar 31, 2026) · CTMX FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 92% equity / 8% debt
Capital structure 98% equity / 2% debt · EV / Revenue 10.72x
STE carries the larger enterprise value at $23.83B against $816.99M; STE trades on the lower EV / Revenue multiple (4.02x vs 10.72x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
STERIS plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CytomX Therapeutics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.27x
0.17x
Net debt / EBITDA
Leverage against operating earnings
—
-0.27x
Cash and equivalents
Liquid reserves on the balance sheet
—
$12.67M
Total debt
Interest-bearing obligations outstanding
$1.93B
$16.89M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
STE vs JNJ
BAXTER INTERNATIONAL INC
STE vs BAX
BECTON DICKINSON & CO
STE vs BDX
ZIMMER BIOMET HOLDINGS, INC.
STE vs ZBH
IDEAYA Biosciences, Inc.
STE vs IDYA
EXELIXIS, INC.
STE vs EXEL
GILEAD SCIENCES, INC.
STE vs GILD
AMGEN INC
STE vs AMGN
AbbVie Inc.
STE vs ABBV
BRISTOL MYERS SQUIBB CO
STE vs BMY
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.